Cargando…

The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication

Chikungunya virus (CHIKV) is the causative agent of chikungunya fever, a disabling disease that can cause long-term severe arthritis. Since the last large CHIKV outbreak in 2015, the reemergence of the virus represents a serious public health concern. The morbidity associated with viral infection em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Policastro, Lucca R., Dolci, Isabela, Godoy, Andre S., Silva Júnior, José V. J., Ruiz, Uriel E. A., Santos, Igor A., Jardim, Ana C. G., Samby, Kirandeep, Burrows, Jeremy N., Wells, Timothy N. C., Gil, Laura H. V. G., Oliva, Glaucius, Fernandes, Rafaela S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317443/ https://www.ncbi.nlm.nih.gov/pubmed/35891332 http://dx.doi.org/10.3390/v14071351

Ejemplares similares

Characterization of the RNA-dependent RNA polymerase from Chikungunya virus and discovery of a novel ligand as a potential drug candidate
por: Freire, Marjorie C. L. C., et al.
Publicado: (2022)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

Imidazonaphthyridine effects on Chikungunya virus replication: Antiviral activity by dependent and independent of interferon type 1 pathways
por: Ruiz, Uriel Enrique Aquino, et al.
Publicado: (2022)

Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
por: Jansen, Anouk M E, et al.
Publicado: (2023)

Actives from MMV Open Access Boxes? A suggested way forward
por: Samby, Kirandeep, et al.
Publicado: (2021)

Cholesterol Reduces Partitioning of Antifungal Drug Itraconazole into Lipid Bilayers
por: Poojari, Chetan, et al.
Publicado: (2020)

Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses
por: Fernandes, Rafaela S., et al.
Publicado: (2020)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles
por: Qiu, Lixin, et al.
Publicado: (2015)

The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo
por: Schloer, Sebastian, et al.
Publicado: (2019)

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
por: Lindsay, Julian, et al.
Publicado: (2021)

Assessment of antifungal efficacy of itraconazole loaded aspasomal cream: comparative clinical study
por: Lamie, Caroline, et al.
Publicado: (2022)

Giving a Hand: Synthetic Peptides Boost the Antifungal Activity of Itraconazole against Cryptococcus neoformans
por: Aguiar, Tawanny K. B., et al.
Publicado: (2023)

Screening of the Pandemic Response Box Reveals an Association between Antifungal Effects of MMV1593537 and the Cell Wall of Cryptococcus neoformans, Cryptococcus deuterogattii, and Candida auris
por: de Oliveira, Haroldo C., et al.
Publicado: (2022)

Sinus bradycardia and chronotropic incompetence associated with single-agent itraconazole antifungal therapy: A case report
por: Tokarev, Julian, et al.
Publicado: (2015)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Itraconazole Loaded Biosurfactin Micelles with Enhanced Antifungal Activity: Fabrication, Evaluation and Molecular Simulation
por: Usman, Faisal, et al.
Publicado: (2023)

Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities
por: Eldesouky, Hassan E., et al.
Publicado: (2020)

The antifungal effect induced by itraconazole in Candida parapsilosis largely depends on the oxidative stress generated at the mitochondria
por: Muñoz-Megías, Mª Luz, et al.
Publicado: (2023)

A Screening of the MMV Pandemic Response Box Reveals Epetraborole as A New Potent Inhibitor against Mycobacterium abscessus
por: Kim, Taeho, et al.
Publicado: (2021)

In Vitro Activities of MMV Malaria Box Compounds against the Apicomplexan Parasite Neospora caninum, the Causative Agent of Neosporosis in Animals
por: Müller, Joachim, et al.
Publicado: (2020)

Intravenous Itraconazole vs. Amphotericin B Deoxycholate for Empirical Antifungal Therapy in Patients with Persistent Neutropenic Fever
por: Park, Sun Hee, et al.
Publicado: (2006)

An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis
por: Tupaki-Sreepurna, Ananya, et al.
Publicado: (2017)

Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever
por: Yoshida, Isao, et al.
Publicado: (2020)

Preparation of Topical Itraconazole with Enhanced Skin/Nail Permeability and In Vivo Antifungal Efficacy against Superficial Mycosis
por: Subedi, Laxman, et al.
Publicado: (2021)

Antifungal activity of essential oils against itraconazole-resistant pathogenic Candida isolated from vulvovaginal candidiasis
por: S. AL-Janabi, Ali Abdul Hussein
Publicado: (2022)

Insights into the role of the cobalt(III)-thiosemicarbazone complex as a potential inhibitor of the Chikungunya virus nsP4
por: Martins, Daniel Oliveira Silva, et al.
Publicado: (2022)

475. Does Metabolite Matter? Defining Target Itraconazole and Hydroxy-itraconazole Serum Levels for Blastomycosis
por: Hess, Danielle, et al.
Publicado: (2022)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Antifungal Activity of Melaleuca alternifolia Essential Oil (TTO) and Its Synergy with Itraconazole or Ketoconazole against Trichophyton rubrum
por: Roana, Janira, et al.
Publicado: (2021)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors
por: Freire, Marjorie C. L. C., et al.
Publicado: (2021)

The Many Faces of Itraconazole Cardiac Toxicity
por: Teaford, Hilary R., et al.
Publicado: (2020)

Trigocherrierin A, a Potent Inhibitor of Chikungunya Virus Replication
por: Bourjot, Mélanie, et al.
Publicado: (2014)

Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis
por: Dhoot, Dhiraj, et al.
Publicado: (2023)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Strong Synergism of Palmatine and Fluconazole/Itraconazole Against Planktonic and Biofilm Cells of Candida Species and Efflux-Associated Antifungal Mechanism
por: Wang, Tianming, et al.
Publicado: (2018)

Heart failure induced by itraconazole
por: Okuyan, Hızır, et al.
Publicado: (2013)

Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry
por: Henß, Lisa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gmiucrtv9oht2gdd7131iu8joo